RxDoctor Payments Data

Kathleen Vickroy

Family · le Claire, IANPI 1831677921

Payments from drug & device makers

$943in general payments, 2019–2025

Across 45 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$420
  • Novo Nordisk$127
  • Pfizer$71
  • Astellas Pharma US Inc$64
  • Dexcom, Inc.$53
  • Exact Sciences$41
  • plus $166 from 7 others

What the payments were for

  • Food & beverage$943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$43,798
Medicare patients
116
Services billed
491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide13$34,878
OzempicSemaglutide20$29,221
EliquisApixaban27$26,235
JardianceEmpagliflozin13$22,658
Sucralfate11$4,497
Atorvastatin Calcium210$1,757
Levothyroxine Sodium205$1,553
Omeprazole93$931
Zolpidem Tartrate ErZolpidem Tartrate20$890
Lisinopril110$722
Duloxetine Hcl28$710
Metoprolol Succinate66$677
Bupropion XlBupropion Hcl22$640
Albuterol Sulfate HfaAlbuterol Sulfate39$604
Gabapentin46$583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$127$64,09933 claims
PfizerEliquis$71$26,23527 claims
Boehringer IngelheimJardiance$27$22,65813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in le Claire

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →